Advanced Science,
Journal Year:
2024,
Volume and Issue:
11(31)
Published: June 19, 2024
Abstract
Small
cell
lung
cancer
(SCLC)
is
a
highly
aggressive
malignancy
characterized
by
rapid
growth
and
early
metastasis
susceptible
to
treatment
resistance
recurrence.
Understanding
the
intra‐tumoral
spatial
heterogeneity
in
SCLC
crucial
for
improving
patient
outcomes
clinically
relevant
subtyping.
In
this
study,
whole
transcriptome‐wide
analysis
of
25
patients
at
sub‐histological
resolution
using
GeoMx
Digital
Spatial
Profiling
technology
performed.
This
deciphered
multi‐regional
heterogeneity,
distinct
molecular
profiles,
biological
functions,
immune
features,
subtypes
within
spatially
localized
histological
regions.
Connections
between
different
transcript‐defined
phenotypes
their
impact
on
survival
therapeutic
response
are
also
established.
Finally,
gene
signature,
termed
ITHtyper,
based
prevalence
levels,
which
enables
risk
stratification
from
bulk
RNA‐seq
profiles
identified.
The
prognostic
value
ITHtyper
rigorously
validated
independent
multicenter
cohorts.
study
introduces
preliminary
tumor‐centric,
regionally
targeted
transcriptome
resource
that
sheds
light
previously
unexplored
SCLC.
These
findings
hold
promise
improve
tumor
reclassification
facilitate
development
personalized
treatments
patients.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: June 26, 2024
Abstract
Tumor
immune
microenvironment
(TIME)
consists
of
intra-tumor
immunological
components
and
plays
a
significant
role
in
tumor
initiation,
progression,
metastasis,
response
to
therapy.
Chimeric
antigen
receptor
(CAR)-T
cell
immunotherapy
has
revolutionized
the
cancer
treatment
paradigm.
Although
CAR-T
emerged
as
successful
for
hematologic
malignancies,
it
remains
conundrum
solid
tumors.
The
heterogeneity
TIME
is
responsible
poor
outcomes
against
advancement
highly
sophisticated
technology
enhances
our
exploration
from
multi-omics
perspective.
In
era
machine
learning,
studies
could
reveal
characteristics
its
resistance
mechanism.
Therefore,
clinical
efficacy
tumors
be
further
improved
with
strategies
that
target
unfavorable
conditions
TIME.
Herein,
this
review
seeks
investigate
factors
influencing
formation
propose
improving
effectiveness
through
perspective,
ultimate
goal
developing
personalized
therapeutic
approaches.
Cell Reports Medicine,
Journal Year:
2024,
Volume and Issue:
5(2), P. 101399 - 101399
Published: Feb. 1, 2024
Colorectal
cancer
(CRC)
is
a
common
malignancy
involving
multiple
cellular
components.
The
CRC
tumor
microenvironment
(TME)
has
been
characterized
well
at
single-cell
resolution.
However,
spatial
interaction
map
of
the
TME
still
elusive.
Here,
we
integrate
multiomics
analyses
and
establish
to
improve
prognosis,
prediction,
therapeutic
development
for
CRC.
We
construct
immune
module
(CCIM)
that
comprises
FOLR2+
macrophages,
exhausted
CD8+
T
cells,
tolerant
CD4+
regulatory
cells.
Multiplex
immunohistochemistry
performed
depict
CCIM.
Based
on
this,
utilize
advanced
deep
learning
technology
predict
chemotherapy
response.
CCIM-Net
constructed,
which
demonstrates
good
predictive
performance
response
in
both
training
testing
cohorts.
Lastly,
targeting
macrophage
therapeutics
used
disrupt
immunosuppressive
CCIM
enhance
vivo.
Heliyon,
Journal Year:
2024,
Volume and Issue:
10(5), P. e27480 - e27480
Published: March 1, 2024
The
tumor
microenvironment
(TME)
with
vital
role
in
cancer
progression
is
composed
of
various
cells
such
as
endothelial
cells,
immune
and
mesenchymal
stem
cells.
In
particular,
innate
macrophages,
dendritic
myeloid-derived
suppressor
neutrophils,
lymphoid
γδT
lymphocytes,
natural
killer
can
either
promote
or
suppress
when
present
the
TME.
An
increase
research
on
cross-talk
between
TME
will
lead
to
new
approaches
for
anti-tumoral
therapeutic
interventions.
This
review
primarily
focuses
biology
their
main
functions
addition,
it
summarizes
several
immune-based
immunotherapies
that
are
currently
tested
clinical
trials.
Cell Communication and Signaling,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: Jan. 19, 2024
Abstract
Breast
cancer,
a
highly
fatal
disease
due
to
its
tendency
metastasize,
is
the
most
prevalent
form
of
malignant
tumors
among
women
worldwide.
Numerous
studies
indicate
that
breast
cancer
exhibits
unique
predilection
for
metastasis
specific
organs
including
bone,
liver,
lung,
and
brain.
However,
different
types
of,
The
understanding
heterogeneity
metastatic
has
notably
improved
with
recent
advances
in
high-throughput
sequencing
techniques.
Focusing
on
modification
microenvironment
crosstalk
between
tumor
cells
situ
cells,
noteworthy
research
points
include
identification
two
distinct
modes
growth
bone
metastases,
influence
type
II
pneumocyte
lung
paradoxical
role
Kupffer
liver
breakthrough
blood-brain
barrier
(BBB)
breach
brain
metastases.
Overall,
this
review
provides
comprehensive
overview
characteristics
shedding
light
pivotal
roles
immune
resident
development
foci.
Graphical
Advanced Science,
Journal Year:
2024,
Volume and Issue:
11(31)
Published: June 19, 2024
Abstract
Small
cell
lung
cancer
(SCLC)
is
a
highly
aggressive
malignancy
characterized
by
rapid
growth
and
early
metastasis
susceptible
to
treatment
resistance
recurrence.
Understanding
the
intra‐tumoral
spatial
heterogeneity
in
SCLC
crucial
for
improving
patient
outcomes
clinically
relevant
subtyping.
In
this
study,
whole
transcriptome‐wide
analysis
of
25
patients
at
sub‐histological
resolution
using
GeoMx
Digital
Spatial
Profiling
technology
performed.
This
deciphered
multi‐regional
heterogeneity,
distinct
molecular
profiles,
biological
functions,
immune
features,
subtypes
within
spatially
localized
histological
regions.
Connections
between
different
transcript‐defined
phenotypes
their
impact
on
survival
therapeutic
response
are
also
established.
Finally,
gene
signature,
termed
ITHtyper,
based
prevalence
levels,
which
enables
risk
stratification
from
bulk
RNA‐seq
profiles
identified.
The
prognostic
value
ITHtyper
rigorously
validated
independent
multicenter
cohorts.
study
introduces
preliminary
tumor‐centric,
regionally
targeted
transcriptome
resource
that
sheds
light
previously
unexplored
SCLC.
These
findings
hold
promise
improve
tumor
reclassification
facilitate
development
personalized
treatments
patients.